(Nasdaq: MDAI) Is A New Low Float Idea Requiring Full Attention (3 Explosive Potential Catalysts)

That's how you end 2023 with a flurry! (Nasdaq: MDAI) Is A New Low Float Idea Requiring Full Attention (3 Explosive Potential Catalysts) January 2nd Dear Reader, That's how you end 2023 with a flurry! Two picks. Two champs. Let's go! On December 28th, we monitored a Nasdaq breakout idea that put together an impressive 2-day surge. From an open of $1.20, it ran to a $2.35 high on Friday for an incredible surge of approximately 95%! Pair that with the previous week's $1.00+ runner that blasted from an open of $3.35 to a high of $4.67 the same day. That's a mind-blowing move of approximately 39% intraday! But that was 2023 and it's officially 2024. It's time to focus on what's next. Right now, a new breakout idea hits your screens in the form of a Nasdaq AI profile. And when it comes to profiles with low floats this small, full attention/focus is required. [Yahoo Finance]( is reporting this profile to have fewer than 10Mn shares in its float which means volatility could appear in a blink. But this isn't only a low float profile, there are a handful of other potential catalysts that could provide it with a breakout spark. How about a [recent uplisting]( to the Nasdaq Capital Market marking a significant milestone and spotlight grabbing move? Yup. This profile could soon be on Wall Street's immediate radar. What about becoming the recipient of a mind-boggling Multi-Mn-Dollar [contract]( That's right. It's got that, too! Listen. The clock's ticking to pull up: *Spectral AI, Inc. (MDAI)* Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. And based on 3 key potential catalysts, MDAI requires full focus. Here's a quick list: #1. A Low Float Could Provide The Potential For Wild Volatility. #2. A Game-Changing Contract Awarded To MDAI For Over $100Mn To Advance DeepView® System! #3. MDAI Looks To Capitalize On A Strong 2023 Full Of Important Company Maneuvers. But more on those in a second... The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. DeepView® - Wound Assessment Technology for Predictive Healing Diagnostics DeepView® Solution: Universal Imaging Platform for Multiple Clinical Indications DeepView SnapShot® Imaging Platform Universal Imaging Platform: DeepView allows for multiple clinical indications while providing easy portability across all healthcare settings AI Predictive Model - AI algorithm integrates image and clinical data for wound healing prediction - Images are analyzed against a proprietary clinical database - Spectral AI has the world’s largest burn biopsy tissue database Meaningful Clinical Outcomes - Spectral AI listens to clinicians about challenges and how we can provide meaningful insights that impact patient care - DeepView strives to transform healthcare by using its proprietary and patented technology Multispectral Imaging and Artificial Intelligence Currently, there is a lack of diagnostic tools for determining tissue health. Multispectral imaging allows the physician to extract intrinsic properties and structures of specific tissues which are not visible to the human eye. Multispectral Imaging Measures Reflectance - Spectral AI system begins its diagnostics by an MSI image capture that sends multiple wavelengths of light from the visible blue field to the deep infrared spectrum. The tissue is illuminated with light of a specific wavelength and the light remitted by the tissue detected. Multispectral Waveforms Classify Tissue Viability - This remitted light results from the specific absorption properties of the tissue or tissue components and is used to differentiate tissue types. DeepView® AI Prediction - This multispectral data is combined with patient clinical data to create the input into the DeepView® artificial intelligence algorithm. The result is an accurate, objective wound healing prediction. Wound Care Solutions for Predictive Healing DeepView’s Day One prediction eliminates subjective biases and provides a more accurate evaluation of wound healing. Informed Wound Care Solutions - Spectral AI’s DeepView® Technology provides accurate information for early determination - Allows for a clear picture of the wound prior to treatment or other interventions Grab Sources: [Company Website.]( [Company Presentation.]( ----- Immediate Focus: MDAI's Explosive Potential Catalysts To Watch Closely Right now, MDAI has multiple potential catalysts that could provide it with a breakout spark in the near term. Here's what to watch for: #1. A Low Float Could Provide The Potential For Wild Volatility. Like many of my major breakout alerts in recent memory, MDAI is no different... It has a low float. [Yahoo Finance]( is reporting a float of approximately 6.27Mn shares for MDAI which means the potential for volatility is extremely high. When another potential catalyst, like company news (whether good or bad), can pair with a low float to create a volatile environment allowing a profile to make excessive vertical moves in the blink of an eye. Which is why it's important to pay attention to companies like MDAI when they drop news like this... #2. A Game-Changing Contract Awarded To MDAI For Over $100Mn To Advance DeepView® System! Wow. Take a look at this mind-blowing news announcement: Spectral MD Awarded BARDA Project BioShield Contract Valued at $149Mn for AI-Driven DeepView® Burn Wound Imaging Technology DALLAS, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been awarded a new contract valued at up to $149Mn by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The contract is for the advanced development of the DeepView® System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI). This multi-year contract includes an initial award of nearly $55Mn to support the clinical validation and FDA clearance of DeepView® for commercial marketing and distribution purposes, a major milestone that enables the technology to become a key component of the U.S. government’s BMCI preparedness efforts. The initial award places up to 30 DeepView® devices at various burn centers and emergency rooms to support the clinical validation study and will transition to being used in routine care upon FDA clearance. The contract also includes options with an additional total value of approximately $95Mn and can be exercised for additional product development, procurement, and deployment of DeepView® at U.S. emergency departments, trauma centers and burn centers in a phased approach. These deployments will enable SMD to conduct health economic and outcome research to support broader clinical adoption of the DeepView® System. ... “We appreciate that our DeepView® platform has been selected to address a critical need in preparing our country for possible BMCI events,” said Wensheng Fan, the Company’s CEO. “This is a significant contract award that enables us to accelerate the late-stage clinical development and commercialization of our DeepView® System. We are most grateful to BARDA for enabling us to help physicians and their burn patients who will benefit from the use of DeepView®. For the first time, there will be an accurate and objective solution in burn wound healing assessment to guide treatment. Spectral MD is committed to the development of impactful medical technologies, and we will aim to bring DeepView® to market as quickly as possible.” ... [Read the full article here.]( But that's not all this company has been up to. 2023 was a momentous year. Just take a look. #3. MDAI Looks To Capitalize On A Strong 2023 Full Of Important Company Maneuvers. This AI company has not been messing around and has been making moves, setting them up for future success. Here's a quick list of what's happened over the last few months alone: 12/19/23 - [Spectral AI Names Industry Veteran and Former Top MiMedx Financial Executive Peter M. Carlson as CFO]( 10/24/23 - [Spectral AI names Prof. Paul Chadwick, Former CEO of the Royal College of Podiatry UK, as Senior Executive for UK and EMEA]( 10/19/23 - [Spectral AI’s DeepView SnapShot® Wound Imaging System, Achieves UKCA Mark and FDA Class 1 Medical Device Classification]( 10/2/23 - [Spectral AI Adds Healthcare Services Leader and Population Health Expert Deepak Sadagopan to Board of Directors]( And like I said, this is only in the last few months! What could early 2024 hold for this Nasdaq AI profile? ----- MDAI Recap - The 3 Top Potential Catalysts To Focus On Now #1. A Low Float Could Provide The Potential For Wild Volatility. #2. A Game-Changing Contract Awarded To MDAI For Over $100Mn To Advance DeepView® System! #3. MDAI Looks To Capitalize On A Strong 2023 Full Of Important Company Maneuvers. ----- Coverage is officially initiated on Spectral AI, Inc. (MDAI). When updates are available, I'll get them out to you quickly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 1/2/24 and ending on 1/3/24 to publicly disseminate information about (MDAI) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (MDAI). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Atlanta Capital Partners LLC, TD Media LLC has been hired for a period beginning on 01/02/2024 and ending on 01/03/2024 to publicly disseminate information about (MDAI:US) via digital communications. We have been paid fifty-one thousand dollars USD. We own zero shares of (MDAI:US). [( Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net